SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
Portfolio Pulse from
SELLAS Life Sciences announced positive preclinical data showing that ASXL1 mutations can predict the response to their drug SLS009 in solid cancers. The study found high efficacy in 67% of ASXL1 mutated cancers compared to 0% in non-mutated ones.
November 27, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences announced that ASXL1 mutations can predict the response to their drug SLS009 in solid cancers, showing 67% efficacy in mutated cases.
The announcement of positive preclinical data is likely to boost investor confidence in SELLAS Life Sciences, as it suggests a targeted approach for SLS009 in treating solid cancers with ASXL1 mutations. This could lead to increased interest and potential future revenue, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90